Is it time to bet on a turnaround?
Yahoo Finance Live's Seana Smith breaks down the stocks trending in the after-hours trading session.
Sam Bankman-Fried's ambition for celebrity endorsements might have snared the "Anti-Hero" singer, but she proved to be smarter than a lot of other famous people.
Have an issue with your financial adviser or looking to hire a new one? Email email@example.com.
After falling for much of the week, the major stock market indexes were gaining ground early Thursday as investors digested the latest unemployment numbers. Last week's initial jobless claims suggest the Federal Reserve's campaign to combat inflation may finally be bearing fruit. Investors used that positive development as an excuse to buy up their favorite beaten-down tech stocks.
Earlier this year, in May, claims were made that Microsoft Corp co-founder Bill Gates owned the majority of America’s farmland. While that is false, with the billionaire amassing nearly 270,000 acres of farmland across the country, compared to 900 million total farm acres, a different billionaire privately owns 2.2 million acres, making him the largest landowner in the U.S. John Malone, the former CEO of Tele-Communications Inc., which AT&T Inc. purchased for more than $50 billion in 1999, has a
Investors searching for that feeling telling you market sentiment is shifting to a more positive outlook have been brought down to earth again. Following 2022’s market behavior to a tee, the recent rally has run into a brick wall. To wit, the S&P 500 notched 5 consecutive negative sessions over the last week with investors mulling over the prospect of a recession. Indeed, financial experts have been sounding the warning bells on the precarious state of the global economy. One of the doomsayers h
At age 51, Anne Schieber was broke and disillusioned. She had worked for the IRS for 23 years and was regarded as one of the agency’s top auditors. But she never got promoted and never earned more than $3,150 in a year. With half her life already behind her, her retirement prospects looked bleak. But Schieber had learned a powerful secret from years of studying the tax returns of America’s richest residents. Over the next 50 years, it earned her a 449,000% return — making Schieber one of the mos
The latest decision from ExxonMobil won't win any popularity contest, but it will make it a champion to its investors. On Thursday, the oil giant...
Retirement-eligible salaried employees at Ford were warned about retiring this year to maximize a lump sum pension payment.
Shares of BioVie (NASDAQ: BIVI) were soaring 23.6% higher as of 11:19 a.m. ET on Thursday. The big jump appears to be the result of a delayed positive reaction by investors after the drugmaker reported results earlier this week from a phase 2 study evaluating experimental therapy NE3107. On Tuesday, BioVie's share price tumbled after the company's Monday evening announcement of results from its phase 2 study of NE3107 in treating Alzheimer's disease and Parkinson's disease.
Buy and hold forever? Not always.
ARK ETF Founder Cathie Wood joins Yahoo Finance Live for a wide-ranging interview on the state of the crypto market, Elon Musk, Fed policy, Teladoc, and more.
The battery innovator is making progress on its lithium-metal batteries, but it still has a couple of years to go before it could start booking meaningful revenue.
Broadcom Inc. (AVGO) delivered earnings and revenue surprises of 1.75% and 0.38%, respectively, for the quarter ended October 2022. Do the numbers hold clues to what lies ahead for the stock?
(Bloomberg) -- Stocks climbed on Friday while the dollar and bond yields fell as investors looked to inflation readings for clues on the path of interest rate hikes.Most Read from BloombergPutin Calls Russian Nukes Deterrent Factor, Says War Risk RisingTesla's Troubles Are Piling Up While Elon Musk Is Distracted With TwitterWNBA Star Griner Freed in One-for-One Swap for Arms DealerElon Musk’s Bankers Consider Tesla Margin Loans to Cut Risky Twitter DebtPeru’s President Accused of Coup After Move
Shares of Summit Therapeutics (NASDAQ: SMMT) were skyrocketing 371.8% higher this week as of the market close on Thursday, according to data provided by S&P Global Market Intelligence. This huge gain came after the company announced on Tuesday that it's licensing bispecific antibody ivonescimab from Chinese drugmaker Akeso. Akeso will retain the rights to market the therapy throughout the rest of the world, including China.
(Bloomberg) -- While Elon Musk is busy overhauling newly acquired Twitter Inc., Tesla Inc. is facing increasingly urgent issues and testing the faith of some of its chief executive’s biggest fans.Most Read from BloombergPutin Calls Russian Nukes Deterrent Factor, Says War Risk RisingTesla's Troubles Are Piling Up While Elon Musk Is Distracted With TwitterWNBA Star Griner Freed in One-for-One Swap for Arms DealerElon Musk’s Bankers Consider Tesla Margin Loans to Cut Risky Twitter DebtPeru’s Presi
Yahoo Finance's Jared Blikre highlights which stocks are making moves at the end of the trading session on Thursday.